Cantor Fitzgerald restated their overweight rating on shares of Mereo BioPharma Group (NASDAQ:MREO – Free Report) in a research note released on Tuesday, Benzinga reports. The firm currently has a $7.00 price objective on the stock.
Other research analysts also recently issued research reports about the stock. Robert W. Baird began coverage on shares of Mereo BioPharma Group in a report on Thursday, June 13th. They set an outperform rating and a $8.00 price objective for the company. Needham & Company LLC restated a buy rating and set a $7.00 price target on shares of Mereo BioPharma Group in a report on Tuesday, August 13th. Baird R W raised Mereo BioPharma Group to a strong-buy rating in a research note on Thursday, June 13th. Finally, Leerink Partners increased their target price on Mereo BioPharma Group from $6.00 to $8.00 and gave the company an outperform rating in a research report on Thursday, June 20th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mereo BioPharma Group currently has a consensus rating of Buy and a consensus target price of $7.50.
Get Our Latest Report on Mereo BioPharma Group
Mereo BioPharma Group Price Performance
Insider Buying and Selling at Mereo BioPharma Group
In other news, CFO Christine Ann Fox sold 9,128 shares of Mereo BioPharma Group stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $4.47, for a total value of $40,802.16. Following the completion of the transaction, the chief financial officer now owns 108,443 shares in the company, valued at approximately $484,740.21. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CFO Christine Ann Fox sold 9,128 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $4.47, for a total value of $40,802.16. Following the sale, the chief financial officer now owns 108,443 shares of the company’s stock, valued at $484,740.21. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Denise Scots-Knight sold 28,611 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $4.47, for a total transaction of $127,891.17. Following the completion of the sale, the chief executive officer now owns 868,967 shares of the company’s stock, valued at approximately $3,884,282.49. The disclosure for this sale can be found here. Insiders have sold a total of 158,175 shares of company stock worth $702,832 over the last ninety days. Company insiders own 4.13% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Rhumbline Advisers lifted its stake in shares of Mereo BioPharma Group by 70.9% during the 2nd quarter. Rhumbline Advisers now owns 6,958 shares of the company’s stock worth $25,000 after acquiring an additional 2,887 shares during the last quarter. Advisors Preferred LLC bought a new stake in shares of Mereo BioPharma Group during the first quarter worth $28,000. SG Americas Securities LLC bought a new stake in shares of Mereo BioPharma Group during the first quarter worth $54,000. BNP Paribas Financial Markets boosted its stake in shares of Mereo BioPharma Group by 581,066.7% during the first quarter. BNP Paribas Financial Markets now owns 17,435 shares of the company’s stock valued at $58,000 after purchasing an additional 17,432 shares during the period. Finally, Index Fund Advisors Inc. bought a new position in shares of Mereo BioPharma Group in the first quarter worth about $99,000. Institutional investors own 62.83% of the company’s stock.
About Mereo BioPharma Group
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
Further Reading
- Five stocks we like better than Mereo BioPharma Group
- What Does Downgrade Mean in Investing?
- When Is the Best Time to Invest in Mutual Funds?
- Investing in Commodities: What Are They? How to Invest in Them
- Is NVIDIA Stock in a Correction or Consolidation?
- What Does a Stock Split Mean?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.